U
GNCA

UBS’s Genocea Biosciences, Inc. GNCA Stock Holding History

UBS’s Portfolio GNCA Stock Details GNCA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		$10K Buy
140
+131
+1,456% +$14.3K ﹤0.01% 8867
2014
Q2 		$1K Buy
+9
New +$1.37K ﹤0.01% 10278

Other funds holding GNCA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PVMCV
Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

UBS's GNCA Position: Q3 2014 in Review

UBS increased its Genocea Biosciences, Inc. (GNCA) stake by 1,456% in Q3 2014, buying an estimated $14.3K and bringing the position to 140 shares worth $10K. The position accounts for ﹤0.01% of the portfolio, ranked #8867.

UBS first reported a position in GNCA in Q2 2014 and has held it in 2 quarters since. 43 funds tracked by Wall St. Rank hold GNCA as of Q3 2014.

  • UBS held 140 shares of Genocea Biosciences, Inc. worth $10K as of Q3 2014.
  • UBS bought 131 Genocea Biosciences, Inc. shares in Q3 2014, an estimated $14.3K.
  • Genocea Biosciences, Inc. made up ﹤0.01% of UBS's portfolio in Q3 2014, its #8867 holding.
  • UBS first reported a position in Genocea Biosciences, Inc. in Q2 2014 and has held it in 2 quarters since.
  • 43 funds tracked by Wall St. Rank held Genocea Biosciences, Inc. as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.